85 results about "Retinal vein occlusions" patented technology

The present invention concerns the use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and / or reversing ocular diseases related with ocular neovascularization. Particularly, the above-mentioned diseases are (wet) age-related macular degeneration, (proliferative) diabetic retinopathy, neovascular glaucoma, retinal vein occlusion, or retinopathy of prematurity (ROP).

The present invention concerns the use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and / or reversing ocular diseases related with ocular neovascularization. Partcularly, the above-mentioned diseases are (wet) age-related macular degeneration, (proliferative) diabetic retinopathy, neovascular glaucoma, retinal vein occlusion, or retinopathy of prematurity (ROP).

Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition.

The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

The invention relates to an artificial transcription factor comprising a polydactyl zinc finger protein targeting specifically a receptor gene promoter fused to an inhibitory or activatory protein domain, a nuclear localization sequence, and a protein transduction domain. In particular examples these receptor gene promoters regulate the expression of the endothelin receptor A, the endothelin receptor B, the Toll-like receptor 4 or the high-affinity IgE receptor. Artificial transcription factors directed to the endothelin A or B receptors are useful in the treatment of diseases modulated by endothelin, such as cardiovascular diseases, and, in particular, eye diseases, e.g. retinal vein occlusion, retinal artery occlusion, macular edema, optic neuropathy, central serous chorioretinopathy, retinitis pigmentosa, Leber's hereditary optic neuropathy, and the like. Artificial transcription factors directed to the Toll-like receptor 4 or the IgE receptor are useful for the treatment of autoimmune disorders, and the like, and allergic disorders, respectively.

A stable liquid formulation includes a fusion protein having an Fc domain of a human immunoglobulin G (IgG), in particular, a protein in which an Fc domain of a human immunoglobulin G (IgG) and a soluble extracellular domain of a vascular endothelial growth factor (VEGF) receptor are fused (e.g., aflibercept)). A composition for stabilizing a protein and a method for stabilizing a protein in which an Fc domain of an IgG and a soluble extracellular domain of a VEGF receptor are fused are disclosed. The present invention improves therapeutic effects on various ophthalmic diseases (e.g., retinal vein occlusion, diabetic macular edema, choroidal neovascularization and wet age-related macular degeneration, etc.) caused by abnormal angiogenesis, while pursuing stabilization of bioactivity through a stable liquid formulation suitable for intravitreal injection of an anti-VEGF-Fc fusion protein including aflibercept.

The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

The present invention provides a Chinese medicine composition for effectively curing ophthalmopathy, in particular, for curing retinopathy due to diabetes and other angiopathy. The invented Chinese medicine composition includes Chinese medicine A and Chinese medicine B. Said Chinese medicine A is made up by using 10 Chinese medicinal materials of forsythia fruit, cirsium, cephalanoplos, ligusticum root, red peony root and others, and Chinese medicine B is made up by using 8 Chinese medicinal materials of white peony root, notoginseng, salvia root, ligusticum root, poria and others. Said invention also provides their application method.

The invention relates to application of digitoflavone-7-O-beta-D-glucuronide in fundus disease treatment, which is characterized in that digitoflavone-7-O-beta-D-glucuronide can be used as a main active component for preparing a medicine treating the pathological change of the fundus. One kind of or a plurality of kinds of natural or synthetic active components with a synergic or auxiliary action with the digitoflavone-7-O-beta-D-glucuronide can be added for preparing a medicine treating fundus diseases. The digitoflavone-7-O-beta-D-glucuronide is used for treating the diabetic pathological change of the retina, the senile pathological change of yellow spots, retinal vein obstruction, and the like, and has an obvious curative effect.

Featured is a device for puncturing tissue of a body, such as the lamina cribosa and methods for treating a CVRO with such a puncturing device. The puncturing device includes a puncture member being generally configured and arranged to locally disrupt tissue proximal an area of the puncture site, to minimize the potential for damage to body parts or tissue immediately adjacent to this area of the puncture site and to facilitate perforation of the tissue at the puncture site. When the lamina cribosa is being punctured, the puncture member is more particularly configured and arranged to locally disrupt connective tissue of the lamina cribosa proximal to and surrounding the central retinal vein while minimizing the potential for structural damage to the central retinal vein. In an exemplary embodiment, the lamina cribosa is repeatedly punctured to strip / locally disrupt connective tissue surrounding the central retinal vein.

A stable liquid formulation includes a fusion protein having an Fc domain of a human immunoglobulin G (IgG), in particular, a protein in which an Fc domain of a human immunoglobulin G (IgG) and a soluble extracellular domain of a vascular endothelial growth factor (VEGF) receptor are fused (e.g., aflibercept)). A composition for stabilizing a protein and a method for stabilizing a protein in which an Fc domain of an IgG and a soluble extracellular domain of a VEGF receptor are fused are disclosed. The present invention improves therapeutic effects on various ophthalmic diseases (e.g., retinal vein occlusion, diabetic macular edema, choroidal neovascularization and wet age-related macular degeneration, etc.) caused by abnormal angiogenesis, while pursuing stabilization of bioactivity through a stable liquid formulation suitable for intravitreal injection of an anti-VEGF-Fc fusion protein including aflibercept.

The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

The invention relates to a Chinese herbal medicine pill for treating fundus hemorrhage. The pill is prepared from 21 Chinese herbal medicines, namely, radix scrophulariae, dried rehmannia roots, Chinese angelica, radix saposhnikoviae, radix paeoniae alba, rhizoma ligustici, moutan bark, radix salviae miltiorrhizae, radix asparagi, radix ophiopogonis, rhizoma coptidis, charred gardeniafruits, liquorice, radix notoginseng, astragalus membranaceus, radix pseudostellariae, frostbitten mulberry leaves, chrysanthemums, pericarpium citri reticulatae, equisetum hyemale and amomum fruits. TheChinese herbal medicine pill is appropriate in medicinecombination and compatibility, functions of all medicines play a synergistic role, comprehensive conditioning is performed on qi, blood, yin and yang of the five internal organs of human bodies while bleeding is stopped, and the purpose of treating both primary and secondary aspects of diseases is achieved, so that the pill has the advantages of good bleeding stop effect, quickness in vision recovery, high recovery rate, low recurrence rate, freedom from obvioustoxic and side effects, convenience in taking, low treatment cost and the like in the aspect of the fundus hemorrhage caused by retinopathy, retinavein occlusion, retinaperiphlebitis and the like caused by diabetes, hypertension and the like and is worthy of popularization and application.

3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile suppresses increases in retinal blood vessel permeability induced by VEGF and therefore can be used as an active component in therapeutic agents or prophylactic agents for a variety of ocular diseases to which VEGF contributes, such as age-related macular degeneration, diabetic retinopathy, macular edema, neovascular maculopathy, retinal vein occlusion, and neovascular glaucoma.

Systems and methods for constructing a widefield image of the retina from a plurality of retinal images. In one aspect, the disclosure concerns constructing a widefield image of the retina from a plurality of retinal images, comprising a base image and a plurality of peripheral images. These techniques enable medical observations of retinal phenomena in patients, such retinal vein occlusion, artery occlusion, retinal detachments, intraocular inflammation, ocular tumors, and the like, that were difficult to detect and impossible to quantify under prior art approaches.

The invention relates to ophthalmic formulations of squalamine or its pharmaceutically acceptable salts for the treatment of conditions of the eye such as, for example, wet age-related macular degeneration (wet AMD), choroidal neovascularization, retinopathy, dry age-related macular degeneration (dry AMD), polypoidal choroidal vasculopathy, neovascularization following ocular surgery, macular edema, retinal venous occlusion, subchoroidal neovascularization, retinal epithelial detachment, pterygum or foveal geographic atrophy of the retinal pigment epithelium.

The invention relates to a capsule for treating retinal vein occlusion. The capsule is characterized in that scutellaria, gegen, salvia, rehmanniae vaporata, cornus officinalis, moutan cortex, white peony root, chrysanthemum, angelica, medlar, dandelion and glycyrrhiza undergo the extraction of concentrated liquid, the concentrated liquid is prepared into extract powder, the extract powder is mixed with centipede powder, scorpion powder, eupolyphaga sinensis powder, long-nosed pit viper powder and pearl powder and stirred evenly, the mixture is subject to drying, sterilization and encapsulating, and the capsule for treating retinal vein occlusion is finally obtained.

The present invention provides biomarkers of oxidative stress in subjects with retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, Fuchs' dystrophy, diabetic macular edema (DME), geographic atrophy, Stargardt's disease, or retinal vein occlusion (RVO), and their use in identifying subjects in need of treatment and methods for staging the severity of the disease.

The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

The invention discloses a compound thrombus-clearing Chinese medicinal preparation and a preparation method thereof. The compound thrombus-clearing Chinese medicinal preparation comprises active ingredients and / or pharmaceutically acceptable additives which are prepared from the following raw materials: 200 to 1,000 grams of sanchi, 50 to 400 grams of astragalus, 40 to 20 grams of radix salviae miltiorrhizae, 60 to 400 grams of figwort root, and 100 to 800 grams of sanchi decoction dreg powder. The Chinese medicinal preparation has the functions of quickening the blood and transforming stasis, expanding blood vessels, increasing blood flow volume, improving blood circulation and microcirculation and tonifying qi and yin and is mainly used for treating the symptoms of retinal vein occlusion caused by blood stasis and qi and yin deficiency, such as blurred vision or paropsis, eyeground blood stasis, fatigued spirit and lack of strength, dry throat and dry mouth. The Chinese medicinal preparation is also applicable to people with the symptoms of stable exertional angina caused by blood stasis and qi and yin deficiency, such as chest distress, chest pain, palptation, flusteredness, shortness of breath, lack of strength, heart vexation and dry mouth.

A method for the prevention or treatment of intraocular angiogenic diseases such as proliferative retinopathy, retinal vein occlusion, retinal artery occlusion or age-related macular degeneration, which comprises administering to a mammal (such as a human) in need thereof a pharmaceutically effective amount of an angiotensin II receptor antagonist such as 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[2′-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]imidazole-5-carboxylic acid.

The invention relates to an artificial transcription factor comprising a polydactyl zinc finger protein targeting specifically a receptor gene promoter fused to an inhibitory or activatory protein domain, a nuclear localization sequence, and a protein transduction domain. In particular examples these receptor gene promoters regulate the expression of the endothelin receptor A, the endothelin receptor B, the Toll-like receptor 4 or the high-affinity IgE receptor. Artificial transcription factors directed to the endothelin A or B receptors are useful in the treatment of diseases modulated by endothelin, such as cardiovascular diseases, and, in particular, eye diseases, e.g. retinal vein occlusion, retinal artery occlusion, macular edema, optic neuropathy, central serous chorioretinopathy, retinitis pigmentosa, Leber's hereditary optic neuropathy, and the like. Artificial transcription factors directed to the Toll-like receptor 4 or the IgE receptor are useful for the treatment of autoimmune disorders, and the like, and allergic disorders, respectively.

The invention belongs to the technical field of intelligent medical treatment, in particular to an algorithm for automatically identifying non-perfusion area of Fundus Fluorescence Angiography (FFA) image and recommending laser photocoagulation area. Aiming at the condition that non-perfusion area quantitative analysis is carried out on FFA images without Artificial Intelligence (AI) technology at home and abroad at present, the algorithm adopts a fundus fluorescence angiography machine with a 55-degree visual field to mark non-perfusion area of retina of an Retinal Vein Occlusion (RVO) patient, and tracks natural disease course, treatment and prognosis of the RVO patient by combining powerful and efficient image analysis and judgment capability as well as clinical big data processing capability of AI, thereby achieving accurate quantitative analysis of the non-perfusion area of the FFA image; and moreover, planning can also be provided for a laser operation with optic disc macular area intelligently avoided.

The invention discloses a sugar-free erigeron breviscapus mixture and a preparation method thereof. The sugar-free erigeron breviscapus mixture consists of the following medicinal raw materials by weight: 6-10 grams of erigeron breviscapus extracting solution (counted by general flavone), 0.1-0.3 grams of hydroxyphenyl ethylester, 2-5 grams of sodium benzoate, 0.1-1 gram of steviosin and 40-100 grams of xylitol. The sugar-free erigeron breviscapus mixture is suitable for treating hemiplegy, rheumatalgia and angina pectoris caused by blood stasis syndrome cerebral infarction as well as ocular fundus retinal vein occlusion and vasculitis skin diseases; is safe, easy and convenient for using; has stable quality; and can be taken by patients suffering from diabetics.

The invention discloses application of a notoginsenoside extract in preparation of drugs for treating xerophthalmia, ocular injuries, ocular vascular disease or ocular neurogenic disease; the xerophthalmia, ocular injuries, ocular vascular disease or ocular neurogenic disease include but not limited to xerophthalmia, retina retrogressive disease, retinal vein obstruction, retinal periphlebitis, hyphema, vitreous hemorrhage, corneal injury, retinal contusion, glaucomatous optic atrophy, drusen, age-related macular degeneration and diabetic retinopathy. A mode of eye local drug delivery adoptedby the invention has the advantages of being low in dose, high in safety, less in adverse reaction, and good in patient compliance; the safety risk brought by injection delivery is avoided; furthermore, after changing the drug delivery route, the metabolic pathways, action mechanisms and other aspects thereof are different from the injection, and better clinical application prospect is realized.

A traditional Chinese medicine preparation is prepared from the following raw materials by weight: 25-30 g of prepared rehmannia root, 15-20 g of angelica sinensis, 10-15 g of radix paeoniae rubra, 8-10 g of rhizoma chuanxiong, 12-18 g of radix bupleuri, 15-20 g of platycodon grandiflorum, 15-20 g of fructus aurantii immaturus, 20-25 g of semen persicae, 15-20 g of radix curcumae, 12-18 g of salvia miltiorrhiza, 12-15 g of caulis spatholobi, 10-15 g of fructus lycii, and 6-10 g of licorice. The traditional Chinese medicine preparation is capable of regulating liver and promoting qi circulation, promoting blood circulation to remove blood stasis, and improving eyesight and dredging collaterals, and plays a role in treating both symptoms and root causes on the retinal vein occlusion. The traditional Chinese medicine preparation has the following clinical effects: 1, the traditional Chinese medicine preparation effectively treats the retinal vein occlusion, the clinical healing and conspicuous effect rate is 66.6%, and the total clinical effective rate is 93.3%; 2, the traditional Chinese medicine preparation can improve eyesight, improves retinal microcirculation and retinal ischemia reperfusion, and promotes retinal hemorrhage and exudation absorption, so as to achieve the purpose of treating the retinal vein occlusion; and 3, the traditional Chinese medicine preparation is convenient to take, and has no toxic or side effect.

The invention discloses a traditional Chinese medicine composition for treating retinal vein obstruction, which consists of the following components according to the parts by weight: 10-15 of felwort, 10-15 of fructus gardeniae, 10-15 of baikal skullcap root, 10-15 of dried rhizome of rehmannia, 10-20 of semen plantaginis, 10-15 of alisma orientale, 5-10 of fiveleaf akebia, 3-10 of liquorice, 5-15 of angelica, 5-10 of salvia miltiorrhiza and 5-8 of sanchi powder. The traditional Chinese medicine composition is mainly used for treating the retinal vein obstruction and particularly has good curative effects on symptoms of liver-gallbladder fire excess, blurred vision or sudden blindness, accompanied bitter taste and testiness, headache and dizziness, pallescence, wiry and rapid pulse, and the like. The traditional Chinese medicine composition has the advantages that: 1. the traditional Chinese medicine composition is a pure traditional Chinese medicine preparation, is convenient to use and has no obvious toxic side effects; 2. the traditional Chinese medicine composition has quick effect, determined curative effect, wide medicine source and low cost; and 3. the traditional Chinese medicine composition can treat both the symptoms and root causes and has good remote effects.

The invention discloses a Chinese medicine composition for treating a fundi disease. The Chinese medicine composition is prepared from the following Chinese medicinal herbs in parts by weight: 40-50 parts of fel ursi, 40-50 parts of rhizoma coptidis from Sichuan of China, 40-50 parts of butterflybush flower, 40-50 parts of notopterygium root, 25-35 parts of pillis ophidiae, 25-35 parts of cortex lycii radicis, 25-35 parts of herba epimedii, 25-35 parts of equisetum hyemale, 25-35 parts of felwort, 10-20 parts of inula flower, 10-20 parts of chamomile flower, 10-20 parts of dianthus superbus, 6-13 parts of nux prinsepiae, 3-9 parts of dragon's blood, 3-9 parts of fructus viticis and 500-1500 parts of fresh wether liver. The Chinese medicine composition can be used for treating fundi diseases caused by any reasons, especially has a special effect of treating symptoms such as retinal arterial obstruction, retinal vein obstruction, optic neuritis, retinal detachment, macular degeneration and the like. Through repeated clinical verifications, the Chinese medicine composition is accurate in treatment effect, good in effect, short in treatment course, high in effect taking speed, and free from side and toxic effects.

The invention relates to the technical field of biomedicine, in particular to a novel retinal vein obstruction mouse model construction method. The novel retinal vein obstruction mouse model construction method comprises the step of intervening a mouse by adopting a photodynamic method and then conducting injection of a Muller cell metabolism inhibitor into a vitreous body. A retinal vein obstruction mouse model prepared by the construction method is stable, can realize lasting retinal edema, can be used for conveniently verifying a drug target and an action mechanism of candidate drugs afterinjection, and provides a new generation of animal model tool for research of retinal vein obstruction diseases.